Gastrointestinal neuroendocrine (carcinoid) tumours: Current diagnosis and management

Medical Journal of Australia

Volumn 193, Issue 1, 2010, Pages 46-52

  Modlin, Irvin M ^a   Moss, Steven F ^b   Oberg, Kjell ^c   Padbury, Robert ^d   Hicks, Rodney J ^e   Gustafsson, Bjorn I ^f   Wright, Nicholas A ^g   Kidd, Mark ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIOCHEMICAL MARKER; CHROMOGRANIN A; KI 67 ANTIGEN; OCTREOTIDE; PASIREOTIDE; SYNAPTOPHYSIN;

APPENDECTOMY; ARTIFICIAL EMBOLISM; AWARENESS; BIOLOGICAL THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CLINICAL EVALUATION; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; GASTROINTESTINAL NEUROENDOCRINE TUMOR; HEMICOLECTOMY; HUMAN; LIVER METASTASIS; METASTASIS; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW;

EID: 77955614650     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03742.x     Document Type: Review

References (40)

1. Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol 2004; 35: 1440-1451.
2. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014: 13-27.
3. Ekeblad S, Skogseid B, Dunder K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-7803.
4. Pape UF, Jann H, Muller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 256-265.
5. Modlin IM, Oberg K, Chung DC, et al. The current status of gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 2008; 9: 61-72.
6. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424.
7. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
8. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
9. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A 1976; 84: 322-330.
10. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008; 20: 1-12.
11. Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15-31.
12. Klimstra DS, Modlin IM, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010; 34: 300-313.
13. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751.
14. Gustafsson BI, Hauso O, Drozdov I, et al. Carcinoid heart disease. Int J Cardiol 2008; 129: 318-324.
15. Stridsberg M, Oberg K, Li Q, et al. Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49-59.
16. Sciarra A, Monti S, Gentile V, et al. Chromogranin A expression in familial versus sporadic prostate cancer. Urology 2005; 66: 1010-1014.
17. Syversen U, Ramstad H, Gamme K, et al. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004; 39: 969-973.
18. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89: 151-160.
19. van der Horst-Schrivers AN, Post WJ, Kema IP, et al. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours. Eur J Cancer 2007; 43: 2651-2657.
20. Bellutti M, Fry LC, Schmitt J, et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci 2009; 54: 1050-1058.
21. Yamagishi H, Fukui H, Shirakawa K, et al. Early diagnosis and successful treatment of small-intestinal carcinoid tumor: useful combination of capsule endoscopy and double-balloon endoscopy. Endoscopy 2007; 39 Suppl 1: E243-E244.
22. Patel KK, Kim MK. Neuroendocrine tumors of the pancreas: endoscopic diagnosis. Curr Opin Gastroenterol 2008; 24: 638-642.
23. Hoeffel C, Job L, Ladam-Marcus V, et al. Detection of hepatic metastases from carcinoid tumor: prospective evaluation of contrast-enhanced ultrasonography. Dig Dis Sci 2009; 54: 2040-2046.
24. Pantongrag-Brown L, Buetow PC, Carr NJ, et al. Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. AJR Am J Roentgenol 1995; 164: 387-391.
25. Janson ET. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. J Endocrinol Invest 2005; 28: 137-140.
26. Marko J, Lamba R, Miller F, et al. OctreoScan positive Crohn's disease mimicking an ileal carcinoid tumor. J Clin Gastroenterol 2008; 42: 66-68.
27. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.
28. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 23-32.
29. Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 2007; 102: 1464-1473.
30. Li AF, Hsu CY, Li A, et al. A 35-year retrospective study of carcinoid tumors in Taiwan: differences in distribution with a high probability of associated second primary malignancies. Cancer 2008; 112: 274-283.
31. Modlin IM, Moss SF, Chung DC, et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008; 100: 1282-1289.
32. Kerstrom G, Hellman P, Hessman O. Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 2005; 19: 717-728.
33. Dierdorf SF. Carcinoid tumor and carcinoid syndrome. Curr Opin Anaesthesiol 2003; 16: 343-347.
34. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008; 286: 69-74.
35. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
36. Van Essen M, Krenning EP, De Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46: 723-734. (Pubitemid 47123757)
37. Landry CS, Scoggins CR, McMasters KM, Martin RC, 2nd. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol 2008; 97: 253-258.
38. Moller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 2005; 112: 3320-3327.
39. Liapi E, Geschwind JF, Vossen JA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 2008; 190: 67-73.
40. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005; 25 Suppl 1: S41-S55.